• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mersana Therapeutics Inc.

    2/14/24 8:43:32 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email
    SC 13G 1 mrsn-sc13g_123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. __)*

     

    Mersana Therapeutics, Inc. 

    (Name of Issuer)

     

    Common Stock 

    (Title of Class of Securities)

     

    59045L106 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 2 of 9

     

    1. NAMES OF REPORTING PERSONS

    SilverArc Capital Management, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    6,420,136
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    6,420,136
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,420,136
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.3%
    12. TYPE OF REPORTING PERSON (see instructions)

    IA
           

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 3 of 9

     

    1. NAMES OF REPORTING PERSONS

    Devesh Gandhi
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Massachusetts
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    6,420,136
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    6,420,136
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,420,136
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.3%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
           

     

     

     

    CUSIP No. 59045L106 

    13G Page 4 of 9

     

    Item 1.

     

    (a)Name of Issuer

     

    Mersana Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    840 Memorial Dr, Cambridge, MA 02139

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor

     

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    59045L106

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 5 of 9

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

    (e)☒ An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

    (g)☒ A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

    (k)☐ Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). 

     

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 6,420,136 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 6,420,136

     

    (b)Percent of Class: 5.3%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 6,420,136

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 6,420,136

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 6,420,136

     

    (e)Percent of Class: 5.3%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 6,420,136

     

    (vii)Sole power to dispose or to direct the disposition of 0.

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 6 of 9

     

    (viii)Shared power to dispose or to direct the disposition of: 6,420,136.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    ☐As of the date of this Report, the aggregate beneficial ownership of the Reporting Persons had been reduced to below five percent (5%).

     

    Item 6.Ownership of More than Five Percent on Behalf of another Person.

     

    SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 6,420,136 shares, or 5.3% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 6,420,136 shares, or 5.3% of the Common Stock believed to be outstanding.  Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 219,229 of these 6,420,136 shares, which equates to 0.2% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 4,065,870 of these 6,420,136 shares, which equates to 3.8% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 1,420,119 of these 6,420,136 shares, which equates to 1.3% of the Common Stock believed to be outstanding. Atom Master Fund L.P., a Cayman Islands exempted limited partnership for which SilverArc acts as investment adviser, may be deemed to beneficially own 714,918 of these 6,420,136 shares, which equates to 0.7% of the Common Stock believed to be outstanding.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

    CUSIP No. 59045L106 

     13G

    Page 7 of 9

     

    Item 10.Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.

     

    Exhibit A Joint Filing Agreement by and between the Reporting Persons dated February 14, 2024.

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 8 of 9

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2024
      Date

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi  

     

     

     

     

    CUSIP No. 59045L106 

    13G Page 9 of 9

     

    EXHIBIT INDEX

     

    Ex.  
       
    A Joint Filing Agreement

     

     

    Get the next $MRSN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mersana Therapeutics Announces Changes in Leadership

      Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

      9/6/23 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Statement About SVB

      CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

      3/10/23 7:10:38 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

      CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

      10/25/21 8:00:00 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

      Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledad

      5/6/25 7:00:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the following presentations related to emiltatug ledadotin (Emi-Le; XMT-1660), Mersana's B7-H4-directed Dolasynthen ADC, will be given at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30-June 3, 2025 at McCormick Place, Chicago, IL: Oral Presentation Details Title: Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin (Emi-Le), a Novel B7-H4-Directe

      4/23/25 10:12:18 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2025, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 26,790 shares of its common stock, to one new employee whose employment commenced in March 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Lis

      4/4/25 4:05:38 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Mersana Therapeutics

      William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

      2/6/25 7:08:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup resumed coverage on Mersana Therapeutics with a new price target

      Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

      11/15/24 8:15:56 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

      3/19/24 7:51:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Chief Accounting Officer Mandelia Ashish converted options into 8,685 shares and sold $2,061 worth of shares (3,554 units at $0.58), increasing direct ownership by 10% to 57,519 units (SEC Form 4)

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      1/17/25 7:27:39 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Protopapas Anna sold $5,009 worth of shares (8,637 units at $0.58) and converted options into 21,250 shares, increasing direct ownership by 8% to 168,041 units (SEC Form 4)

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      1/17/25 7:26:45 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Sci.&Tech. Officer Lowinger Timothy B converted options into 19,791 shares and sold $4,668 worth of shares (8,048 units at $0.58), increasing direct ownership by 5% to 257,673 units (SEC Form 4)

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      1/17/25 7:25:05 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

      SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/15/24 4:45:57 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 5:45:55 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 6:01:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Financials

    Live finance-specific insights

    See more
    • Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

      Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledad

      5/6/25 7:00:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

      Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least one topoisomerase-1 inhibitor (topo-1) ADCPlan to present additional clinical data from dose escalation and backfill cohorts in 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business upda

      3/3/25 7:01:23 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

      CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Invest

      2/24/25 4:01:28 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    SEC Filings

    See more
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      5/6/25 7:11:55 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mersana Therapeutics Inc.

      SCHEDULE 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      4/30/25 11:23:39 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Mersana Therapeutics Inc.

      DEFA14A - Mersana Therapeutics, Inc. (0001442836) (Filer)

      4/29/25 6:05:04 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care